UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)

加州大学洛杉矶分校和加州理工学院生物工程师综合心血管医学 (iCMB)

• 批准号: 10038297
• 负责人: Tzung K Hsiai
• 金额: $ 14.33万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10038297
• 关键词: Biomedical Engineering; Cardiovascular system; Medicine

ABSTRACT This T32 program represents a new paradigm for training biophysical scientists and engineers to traverse cardiovascular medicine. The convergence of engineering with medicine is transforming clinical and patient care via advances in flexible electronics for sensing and imaging, coupled with machine learning, which has introduced new innovations to confront the rising endemic of cardiometabolic disorders. The University of California at Los Angeles (UCLA) and the California Institute of Technology (Caltech) are partnering to develop the UCLA/Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB) Program, that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post- doctoral engineers or biophysical scientists into leadership roles in academia and industry. The approach is to strengthen individualized training in 1) advanced sensing or 2) imaging coupled with machine learning to address 3) cardiometabolic disease. The iCMB program will be built upon two successful Caltech and UCLA joint training programs: the Medical Scientist Training Program (MSTP) for MD-PhD students and the unique Subspecialty Training and Advanced Research Program (STAR) for fellowship-level physicians to obtain a PhD. The partnerships with the industry leaders from Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences have enriched our internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and under-represented minorities. To implement this iCMB Program, we have developed a novel mentoring and self-evaluating structure in the inclusion of 24 seasoned mentors, 4 emerging faculty, 22 Clinical Faculty (42% female), and 10 industry leaders. Each iCMB scholar will have co-mentorships: a primary mentor from cardiometabolic medicine and a secondary from enabling technologies or industry. In Year 1, iCMB scholars will develop fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iCMB scholar will have an option 1) to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 2) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iCMB scholar. Our Vice Provost for UCLA Graduate Education has also committed supplemental trainee support to enhance the diversity of trainees. Therefore, the complementary and synergistic strengths of the Caltech/UCLA iCMB Program provide a new infusion of workforce prepared to solve the worldwide endemic of cardiometabolic disease.

抽象的 该T32程序代表了一种培训生物物理科学家和工程师遍历的新范式 心血管医学。工程与药物的融合正在改变临床和患者 通过灵活电子的进步进行感测和成像的护理，再加上机器学习， 引入了新的创新，以面对心脏代谢疾病的中断流行。大学 加利福尼亚州的洛杉矶（UCLA）和加利福尼亚理工学院（CALTECH）正在合作开发 UCLA/Caltech综合心血管医学用于生物工程（ICMB）计划，这将是 正式为期两年的结构化课程，重点是招募不足的后 博士工程师或生物物理科学家在学术界和工业中担任领导角色。方法 是在1）高级感应中加强个性化训练，或2）成像与机器的成像 学习解决3）心脏代谢疾病。 ICMB计划将建立在两个成功的基础上 Caltech和UCLA联合培训计划：MD-PHD的医学科学家培训计划（MSTP） 学生和独特的奖学金培训和高级研究计划（Star）奖学金级别 医生获得博士学位。与Amgen，Johnson＆Johnson的行业领导人的合作伙伴关系， Medtronic和Edwards Lifesciences丰富了我们的实习，指导和领导力计划。 加州理工学院多样性中心和加州大学洛杉矶分校的教职员工多样性与发展办公室都支持 妇女的科学技术工程与数学研讨会（STEM）和代表性不足的讲习班 少数民族。为了实施此ICMB计划，我们开发了一种新颖的指导和自我评估 包括24位经验丰富的导师，4位新兴教师，22位临床教师（42％的女性）和10个的结构 行业领导者。每个ICMB学者都将拥有会议：心脏代谢的主要导师 医学和辅助技术或行业的次要。在第一年，ICMB学者将发展 高级成像，传感器或计算的基本知识以及道德的教学培训 生物医学研究和出版物。在第二年，ICMB学者将有一个选项1）参加 UCLA临床转化科学的临床和转化研究途径证书 FDA监管科学的研究所（CTSI）或法律与技术（BE188/299）；和/或2）参加 UCLA CTSI赞助的专业发展为学术或行业职业做准备。两个都 加州理工学院和加州大学洛杉矶分校的院长为每个ICMB学者提供了匹配资金。我们为加州大学洛杉矶分校的副教务长 研究生教育还提供了补充学员的支持，以增强学员的多样性。 因此，加州理工学院/UCLA ICMB计划的互补和协同优势提供了新的 注入准备解决心脏代谢疾病全球流行的劳动力。